Anti-idiotypic antibody mimicking a T-antigen-specific lectin inhibits human epithelial tumor cell proliferation

Immunology and Cell Biology

Volumn 88, Issue 8, 2010, Pages 787-794

  Sendra, Victor G ^a   Zlocowski, Natacha ^a   Nores, Gustavo A ^a   Irazoqui, Fernando J ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Agaricus bisporus lectin; anti idiotypic antibody; related T antigens; tumor cell proliferation

Indexed keywords

ANTIGEN; ANTIIDIOTYPIC ANTIBODY; CARBOHYDRATE BINDING PROTEIN; GLYCAN; IMMUNOGLOBULIN G; LECTIN; PROTEIN G; T LYMPHOCYTE ANTIGEN; TN ANTIGEN;

AFFINITY CHROMATOGRAPHY; AGARICUS BISPORUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PROTEIN PURIFICATION; TUMOR CELL;

AGARICUS; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, VIRAL, TUMOR; APOPTOSIS; CARCINOMA; CELL GROWTH PROCESSES; CELLS, CULTURED; CHROMATOGRAPHY, AFFINITY; EPITOPES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; LECTINS; MICE; PROTEIN BINDING; RABBITS;

AGARICUS BISPORUS; BASIDIOMYCOTA; ORYCTOLAGUS CUNICULUS;

EID: 78649325977     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.49     Document Type: Article

References (50)

1. Varki A, Cummings RD, Esko JD, Freeze HH, Staley P, Bertozzi CR et al. Essentials of Glycobiology. Cold Spring Harbor Laboratory Press: New York, 2008.
2. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycody-namics and functions. EMBO Rep 2006; 7: 599-604.
3. Hanisch FG, Ninkovic T. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr Protein Pept Sci 2006; 7: 307-315.
4. Yu LG. The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J 2007; 24: 411-420.
5. Cao Y, Merling A, Karsten U, Goletz S, Punzel M, Kraft R et al. Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int J Cancer 2008; 123: 89-99.
6. Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B et al. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients. Breast Cancer Res Treat 2007; 101: 17-25.
7. Baldus SE, Zirbes TK, Hanisch FG, Kunze D, Shafizadeh ST, Nolden S et al. Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: a clinicopathologic study of 264 patients. Cancer 2000; 88: 1536-1543.
8. Kawamura YI, Kawashima R, Fukunaga R, Hirai K, Toyama-Sorimachi N, Tokuhara M et al. Introduction of Sd(a) carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis. Cancer Res 2005; 65: 6220-6227.
9. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem 2007; 282: 773-781.
10. Kawaguchi T, Takazawa H, Imai S, Morimoto J, Watanabe T. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women. Breast Cancer Res Treat 2005; 92: 223-230.
11. Kurtenkov O, Klaamas K, Sergeyev B, Chuzmarov V, Miljukhina L, Shljapnikova L. Better survival of Helicobacter pylori infected patients with early gastric cancer is related to a higher level of Thomsen-Friedenreich antigen-specific antibodies. Immunol Invest 2003; 32: 83-93.
12. Ravn P, Stahn R, Danielczyk A, Faulstich D, Karsten U, Goletz S. The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs. Cancer Immunol Immunother 2007; 56: 1345-1357.
13. Irazoqui FJ, Vides MA, Nores GA. Structural requirements of carbohydrates to bind Agaricus bisporus lectin. Glycobiology 1999; 9: 59-64.
14. Yu LG, Milton JD, Fernig DG, Rhodes JM. Opposite effects on human colon cancer cell proliferation of two dietary Thomsen-Friedenreich antigen-binding lectins. J Cell Physiol 2001; 186: 282-287.
15. Carrizo ME, Capaldi S, Perduca M, Irazoqui FJ, Nores GA, Monaco HL. The anti-neoplastic lectin of the common edible mushroom (Agaricus bisporus) has two binding sites, each specific for a different configuration at a single epimeric hydroxyl. J Biol Chem 2005; 280: 10614-10623.
16. Yu LG, Fernig DG, Smith JA, Milton JD, Rhodes JM. Reversible inhibition of proliferation of epithelial cell lines by Agaricus bisporus (edible mushroom) lectin. Cancer Res 1993; 53: 4627-4632.
17. Irazoqui FJ, Zalazar FE, Chiabrando GA, Romero O, Vides MA. Differential reactivity of Agaricus bisporus lectin with human IgA subclasses in gel precipitation. J Immunol Methods 1992; 156: 199-204.
18. Goldstein IJ, Hayes CE. The lectins: carbohydrate-binding proteins of plants and animals. Adv Carbohydr Chem Biochem 1978; 35: 127-340.
19. Irazoqui FJ, Sendra VG, Lardone RD, Nores GA. Immune response to Thomsen-Friedenreich disaccharide and glycan engineering. Immunol Cell Biol 2005; 83: 405-412.
20. Monzavi-Karbassi B, Shamloo S, Kieber-Emmons M, Jousheghany F, Luo P, Lin KY et al. Priming characteristics of peptide mimotopes of carbohydrate antigens. Vaccine 2003; 21: 753-760.
21. Hoess R, Brinkmann U, Handel T, Pastan I. Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene 1993; 128: 43-49.
22. Fernandez LE, Alonso DF, Gomez DE, Vazquez AM. Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Rev Vaccines 2003; 2: 817-823.
23. Perez A, Lombardero J, Mateo C, Mustelier G, Alfonso M, Vazquez AM et al. Immu-nogenetic analysis of variable regions encoding AB1 and gamma-type AB2 antibodies from the NeuGc-containing ganglioside family. Hybridoma 2001; 20: 211-221.
24. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodŕiguez E, Bitton R et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002; 168: 2523-2529.
25. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA. Anti-idiotype vaccine against cancer. Immunol Lett 2000; 74: 51-58.
26. de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 2007; 26: 3594-3602.
27. Schwartz-Albiez R, Laban S, Eichmüller S, Kirschfink M. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? Autoimmun Rev 2008; 7: 491-495.
28. Sztein MB, Michell GF. Recent advances in immunology: impact on vaccine development. In: Levine MM, Wodroow GC, Kaper JB, Cobon GS (eds). New Generation Vaccine. Marcell Dekker: New York, 1997, 99-125.
29. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006; 6: 99-106.
30. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007; 7: 357-369.
31. Weiner LM. Building better magic bullets\improving unconjugated monoclonal antibody therapy for cancer. Nat Rev Cancer 2007; 7: 701-706.
32. Lotan R, Skutelsky E, Danon D, Sharon N. The purification, composition, and specificity of the anti-T lectin from peanut (Arachis hypogaea). J Biol Chem 1975; 250: 8518-8523.
33. Dahlenborg K, Hultman L, Carlsson R, Jansson B. Human monoclonal antibodies specific for the tumour associated Thomsen-Friedenreich antigen. Int J Cancer 1997; 70: 63-71.
34. Irazoqui FJ, Jansson B, Lopez PH, Nores GA. Correlative fine specificity of several Thomsen-Friedenreich disaccharide-binding proteins with an effect on tumor cell proliferation. J Biochem (Tokyo) 2001; 130: 33-37.
35. Yu LG, Jansson B, Fernig DG, Milton JD, Smith JA, Gerasimenko OV et al. Stimulation of proliferation in human colon cancer cells by human monoclonal antibodies against the TF antigen (galactose beta1-3 N-acetyl-galactosamine). Int J Cancer 1997; 73: 424-431.
36. Chaturvedi R, Heimburg J, Yan J, Koury S, Sajjad M, Abdel-Nabi HH et al. Tu m o r immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Frie-denreich alpha-linked antigen. Appl Radiat Isot 2008; 66: 278-287.
37. Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, Wild L et al. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia 2006; 8: 939-948.
38. Jerne NK, Roland J, Cazenave PA. Recurrent idiotopes and internal images. EMBO J 1982; 1: 243-247.
39. Irazoqui FJ, Lopez PH, Vides MA, Nores GA. Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage. Glycobiology 2000; 10: 781-787.
40. Sarkar K, Das PK. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. J Immunol 1997; 158: 5357-5365.
41. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004; 35: 455-462.
42. Kato K, Jeanneau C, Tarp MA, Benet-Pagès A, Lorenz-Depiereux B, Bennett EP et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006; 281: 18370-18377.
43. Tarp MA, Sorensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007; 17: 197-209.
44. Ragupathi G, Koganty RR, Qiu D, Lloyd KO, Livingston PO. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj J 1998; 15: 217-221.
45. Erdile LF, Smith D, Berd D. Whole Cell ELISA for detection of tumor antigen expression in tumor samples. J Immunol Methods 2001; 258: 47-53.
46. Irazoqui FJ, Lopez PH, Mandel U, Nores GA. Influence of terminal residue on adjacent disaccharide immunogenicity. Mol Immunol 2002; 38: 825-831.
47. Coligan JE, Bierer BE, Margulies DH, Shevach EM, Strober W. Short Protocols in Immunology. Unit 2.14: Measurement of apoptosis and other forms of cell death: microscopic quantification of cell viability using vital and fluorescent dyes. John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2005, p 2.70.
48. Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005; 5: 12.
49. Span LF, Pennings AH, Vierwinden G, Boezeman JB, Raymakers RA, de Witte T. The dynamic process of apoptosis analyzed by flow cytometry using Annexin-V/propidium iodide and a modified in situ end labeling technique. Cytometry 2002; 47: 24-31.
50. van Sorge NM, Yuki N, Jansen MD, Nishimoto Y, Susuki K, Wokke JH et al. Leukocyte and complement activation by GM1-specific antibodies is associated with acute motor axonal neuropathy in rabbits. J Neuroimmunol 2007; 182: 116-123.